Application of DANCR inhibitor in preparation of medicine for treating depression

By inhibiting the expression of LncRNA DANCR, the biomarker deficiency problem in the treatment of depression is solved, and the proliferation of nerve cells is significantly promoted, apoptosis and inflammatory factors are inhibited, providing a new treatment for depression.

CN119033804AActive Publication Date: 2024-11-29JINAN UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410980576.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-29
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

Complex causes and multiple factors of depression lead to difficulties in treatment, and there is a lack of effective biomarkers for targeted treatment.

Method used

By constructing an in vitro model of depression, the key role of LncRNA DANCR in depression was confirmed, and the LncRNA DANCR inhibitor was developed to promote nerve cell proliferation, inhibit nerve cell apoptosis, and significantly inhibit inflammatory factors levels to treat nerves. Sexual inflammation.

Benefits of technology

It provides new therapeutic targets and strategies to significantly promote nerve cell proliferation, inhibit apoptosis, reduce the level of inflammatory factors, effectively treat depression and neurotic inflammation, and prevent further development of the disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033804A_ABST
    Figure CN119033804A_ABST
Patent Text Reader

Abstract

The invention relates to an application of an LncRNA-DANCR inhibitor in preparation of a medicine for treating depression. A large number of researches find that LncRNA DANCR is one of key factors causing depression and promoting depression development. After the expression level of the DANCR is inhibited by utilizing the inhibitor, the proliferation of nerve cells can be effectively promoted, and the apoptosis of the nerve cells can be inhibited. Meanwhile, DANCR has a key influence effect on inflammations, especially neurological inflammations and related inflammatory factors thereof. Results show that by inhibiting the expression of DANCR, the levels of TNF-alpha, IL-6, IL-2, IL-1beta, IFN-gamma, G-CSF and other inflammatory factors in vivo can be significantly inhibited, so that neurological inflammation is effectively treated, and further development of depression conditions is prevented. According to the present invention, the mechanism research results show that the obvious mutual combination effect exists between the LncRNA DANCR and the DDX3X, and the LncRNA DANCR can protect the DDX3X protein, slow the degradation of the DDX3X protein, promote the stability of the DDX3X, increase the abundance of the DDX3X protein, and mediate the DDX3X protein to promote the inflammasome activation;
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine and molecular biology, and specifically relates to the application of LncRNA-DANCR inhibitor in the preparation of medicine for treating depression. Background Art

[0002] Depression is a chronic recurrent disease and a type of depressive disorder. Its main symptoms include low mood, decreased interest, slow thinking, decreased attention and memory, self-denial, poor appetite, decreased activity, etc. The prevalence of depression is on the rise. Currently, depression has become the fourth largest disease in the world. According to conservative estimates, there are 350 million depression patients in the world, and 10-15% of depression patients eventually die from suicide.

[0003] To date, the cause of depression is not very clear. Studies have shown that many biological, psychological and social environmental factors may be involved in the pathogenesis of depression. Biological factors mainly involve genetics, neurochemistry, neuroendocrine, and neural regeneration; psychological susceptibility closely related to depression is pre-morbid personality traits, such as depressive temperament. Encountering stressful life events in adulthood is an important trigger for clinically significant depressive episodes. However, these factors do not work alone. The interaction between genetics and environmental or stress factors, as well as the timing of the occurrence of such interactions, has an important influence on the occurrence of depression. Due to the complex and difficult to determine causes of depression, its treatment is extremely difficult. Therefore, finding biomarkers closely related to depression for targeted treatment has become a key problem that needs to be solved urgently. Summary of the invention

[0004] In view of the deficiencies in the prior art, the present invention provides the use of LncRNA-DANCR inhibitors in the preparation of drugs for treating depression. The present invention, by constructing an in vitro model of depression, confirms that LncRNA DANCR is one of the key factors that cause depression and promote the development of depression. By inhibiting the expression of DANCR, the proliferation of nerve cells can be effectively promoted and the apoptosis of nerve cells can be inhibited. At the same time, the levels of inflammatory factors such as TNF-α, IL-6, IL-2, IL-1β, IFN-γ, G-CSF, etc. in the body can be significantly inhibited, thereby effectively treating neuroinflammation and preventing the further development of depression.

[0005] In order to solve the above technical problems, the present invention is implemented through the following technical solutions.

[0006] The first aspect of the present invention provides use of a LncRNA DANCR inhibitor in the preparation of a drug for preventing and / or treating depression.

[0007] It should be understood that, in the context of the present invention, the LncRNA DANCR and the like listed are LncRNA types known in the art, and those skilled in the art are capable of obtaining molecular biological information related to LncRNA DANCR and the like from conventional databases, such as sequences and the like. The expressions "LncRNA DANCR", "LncRNA-DANCR", "DANCR" and the like are all expressions of the same meaning, and are simplified expressions of long non-coding RNA-DANCR. The LncRNA DANCR inhibitor refers to a substance that can specifically downregulate and / or inhibit the expression level of LncRNA DANCR in cells and / or tissues and / or the activity of its mature LncRNA, such as siRNA, sgRNA, shRNA, etc., as long as it can achieve knockdown and / or knockout of LncRNA DANCR. The LncRNA DANCR inhibitor can be purchased or synthesized through commercial channels according to experimental requirements, or it can be designed and synthesized based on the sequence of LncRNA DANCR.

[0008] Preferably, the LncRNA DANCR inhibitor is selected from siRNA (siDANCR) designed based on the LncRNA DANCR gene.

[0009] Preferably, the siRNA sequence designed based on the LncRNA DANCR gene is as shown in SEQ ID NO: 1, which is 5'-GGTGAAGTAGTCGCACATTTATT-3' (sense); accordingly, its antisense sequence is as shown in SEQ ID NO: 2, which is 5'-TAAATGTGCGACTACTTCACCTT-3' (antisense).

[0010] The second aspect of the present invention provides the use of a LncRNA DANCR inhibitor in the preparation of a drug for treating neuroinflammation and / or improving physiological indicators related to neuroinflammation.

[0011] Preferably, the LncRNA DANCR inhibitor is selected from siRNA (siDANCR) designed based on the LncRNA DANCR gene.

[0012] Preferably, the siRNA sequence designed based on the LncRNA DANCR gene is as shown in SEQ ID NO: 1, which is 5'-GGTGAAGTAGTCGCACATTTATT-3' (sense); accordingly, its antisense sequence is as shown in SEQ ID NO: 2, which is 5'-TAAATGTGCGACTACTTCACCTT-3' (antisense).

[0013] Preferably, the physiological indicators related to neuroinflammation are selected from one or more of TNF-α, IL-6, IL-2, IL-1β, IFN-γ, G-CSF, and DDX3X.

[0014] The third aspect of the present invention provides a pharmaceutical composition for preventing and / or treating depression, comprising a LncRNA DANCR inhibitor and a pharmaceutically acceptable excipient.

[0015] Preferably, the LncRNA DANCR inhibitor is selected from siRNA (siDANCR) designed based on the LncRNA DANCR gene.

[0016] Preferably, the siRNA sequence designed based on the LncRNA DANCR gene is as shown in SEQ ID NO: 1, which is 5'-GGTGAAGTAGTCGCACATTTATT-3' (sense); accordingly, its antisense sequence is as shown in SEQ ID NO: 2, which is 5'-TAAATGTGCGACTACTTCACCTT-3' (antisense).

[0017] Preferably, the pharmaceutically acceptable excipient is selected from one or more of a solvent, a solubilizer, a wetting agent, an antioxidant, an antibacterial agent, a chelating agent, and a surfactant.

[0018] Inflammation is a defensive response of tissues to biological, physical, chemical and other damaging factors, and the immune response produced in the brain is called neuroinflammation. Neuroinflammation acts as a "double-edged sword" in the central nervous system. On the one hand, it can maintain the body's homeostasis, and on the other hand, excessive reaction can also damage normal tissues and organs. There are generally two ways to cause neuroinflammation. First, some peripheral cytokines can enter the brain through the blood-brain barrier and cause central nervous inflammation. Secondly, the central immune system itself can also cause inflammatory reactions. The microglia in the central nervous system have a similar effect to the surrounding macrophages. When the brain is subjected to external stimuli such as trauma or infection, microglia will be activated and secrete a large number of proinflammatory cytokines, chemokines and reactive oxygen species. Once inflammation is overactivated, it will cause pathological damage. In the classical inflammasome pathway, when the formation of NLRP3 inflammasome activates Caspase-1, the body's chronic stress stimulation is converted into an inflammatory response, causing inflammatory damage to the brain, which can lead to the occurrence of neurological diseases.

[0019] DDX3 is a member of the DEAD (Asp-Glu-Ala-Asp)-box helicase family and is involved in almost all aspects of eukaryotic RNA metabolism. The human genome encodes two types of DDX3 genes: DDX3X and its homolog DDX3Y. DEAD-box RNAhelicase 3 (DDX3X), as a highly conserved member of the DEAD-box protein family, is a key RNA binding protein and transcription cofactor with multiple functions such as immune regulation, viral manipulation and tumor progression. Studies have found that in the absence of DDX3X, the activation of the NLRP3 inflammasome is strongly inhibited, so reducing the expression of DDX3X is an important way to inhibit NLRP3 activation.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] (1) The present invention has confirmed through a large number of studies that LncRNA DANCR plays an important role in depression and neuroinflammation. LncRNA DANCR can inhibit the proliferation of nerve cells and promote the apoptosis of nerve cells. After the expression of LncRNA DANCR is inhibited by an inhibitor, the proliferation of nerve cells can be significantly promoted and the apoptosis of nerve cells can be inhibited. This provides a new therapeutic target for the treatment of depression and a new idea and strategy for the subsequent development of drugs for the diagnosis and treatment of depression.

[0022] (2) The present invention further studies the mechanism of action of LncRNA DANCR and finds that LncRNA DANCR is mainly located in the cell nucleus and has obvious mutual binding with DDX3X, which can protect DDX3X protein, slow down its degradation, promote DDX3X stability, increase the abundance of DDX3X protein, and then mediate DDX3X protein to promote inflammasome activation. By inhibiting the expression level of LncRNA DANCR, it helps to reduce the expression level of DDX3X protein in the body, inhibit the levels of inflammatory factors such as TNF-α, IL-6, IL-2, IL-1β, IFN-γ, G-CSF, etc. in the body, thereby inhibiting the inflammatory response, which plays an important role in alleviating and treating depression and preventing the further development of depression. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Schematic diagram of the expression level results of LncRNA DANCR in rats of the depression model group and the normal group.

[0024] Figure 2 Schematic diagram of the effects of different concentrations of CORT on PC12 cell proliferation.

[0025] Figure 3 Schematic diagram of the effect of siDANCR on PC12 cell proliferation.

[0026] Figure 4 Schematic diagram of the effect of siDANCR on PC12 cell apoptosis.

[0027] Figure 5 This is a schematic diagram showing the effects of siDANCR on the expression of intracellular inflammatory factors such as TNF-α, IL-6, IL-2, IL-1β, IFN-γ, and G-CSF.

[0028] Figure 6 Schematic diagram of the results of the cell nucleus-cytoplasm separation experiment.

[0029] Figure 7 Schematic diagram of fluorescence in situ hybridization experimental results.

[0030] Figure 8 Schematic diagram of the pull-down experiment results.

[0031] Fig. 9 Schematic diagram of RNA binding protein co-immunoprecipitation experiment results.

[0032] Fig.10 Schematic diagram of Western blot experimental results. DETAILED DESCRIPTION

[0033] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0034] In the absence of special instructions, the cell lines including PC12 listed in the context of the present invention are cultivated according to conventional methods. All cell lines are identified by short tandem repeat analysis of China Type Culture Collection (Wuhan), and PCR detection kit (Shanghai Biothrive Sci) is used to verify whether there is mycoplasma contamination, and cryopreserved in liquid nitrogen and used for subsequent experiments. In the reagent used in the present invention, all are obtained commercially. The experimental method used in the present invention, such as cell culture, nucleic acid extraction, genome sequencing, primer design, PCR, cell transfection, fluorescent staining, animal experiment, cell proliferation experiment, apoptosis experiment, etc. are all conventional methods and techniques in this area. For the development of animal experiments, the experimental scheme is approved by the Animal Experiment Ethics Committee of Jinan University and follows its criteria.

[0035] Representative results from repeated biological experiments were presented in the context figures, and the data were presented as mean ± SD and mean ± SEM as specified in the figure. All experiments were repeated at least three times. The data were analyzed using GraphPad Prism 8.0 or SPSS 22.0 software. Conventional medical statistical methods such as t-test, chi-square test, and analysis of variance were used to compare the mean differences between two or more groups. p < 0.05 was considered a significant difference.

[0036] Example 1

[0037] Female rats weighing about 250g were taken, and were given free access to water and pelleted feed. The animal room was lit 12h / 12h alternately, the relative humidity was maintained at 60-75%, and the temperature was 22-25℃. The rats were adapted for one week. The rats were then randomly divided into two groups, 10 in each group, and recorded as Group 1 and Group 2. Group 1 was raised normally without any treatment; Group 2 was used to construct a chronic unpredictable mild stress (CUMS) depression model, and the specific method was as follows: one week was a treatment cycle, and various stresses were randomly given for 6 weeks: stress 16h water deprivation, 16h food deprivation, 1h empty bottle, 8h cage tilt (45 degrees), 16h crowding (8-10 per cage), 24h continuous lighting, 8h wet bedding, 5min heat stimulation (45℃), 5min cold stimulation (4℃). Rats received a stress stimulus every day, and the same stimulus was not repeated for two consecutive days to minimize the predictability of each stimulus. Subsequently, whole transcriptome sequencing technology was used to analyze the expression profile of the cerebral cortex of rats in group 1 and group 2, and differentially expressed LncRNAs were screened. The results showed that there were significant differences in the expression of 20 LncRNAs between the depression model group and the normal group, of which 12 LncRNAs were significantly upregulated and 8 LncRNAs were downregulated. Among them, the expression difference of LncRNA DANCR was the most significant (see Figure 1 ).

[0038] Subsequently, corticosterone was used to construct an in vitro depression model. The specific steps are as follows:

[0039] (1) Rat adrenal medullary pheochromocytoma differentiated cell line (PC12 cells) were cultured in RPMI-1640 (Hyclone) medium containing 10% fetal bovine serum for 24 h at 5% CO2 and 37°C.

[0040] (2) Corticosterone (CORT, MCE) was dissolved in DMSO, filtered and sterilized, and added to serum-free RPMI-1640 medium to adjust the CORT concentrations to 0 μM, 20 μM, 50 μM, 100 μM, and 200 μM, respectively.

[0041] (3) After the cells have grown to the bottom of the well, the upper layer of cell fluid was aspirated and the serum-free RPMI-1640 medium containing different concentrations of CORT prepared in step (2) was added. The cells were cultured in a 5% CO2, 37°C cell culture incubator for 24 h. CCK8 solution was added and the cells were incubated for another 2 h. The absorbance was measured at 450 nm using an ELISA reader to observe the effect of CORT on the proliferation of PC12 cells.

[0042] The results are as follows Figure 2As shown. The results showed that adding different concentrations of CORT to PC12 cells could reduce cell viability. By comparing with the untreated control group, CORT treatment with concentrations of 20μM, 50μM, 100μM, and 200μM significantly inhibited cell proliferation, and the difference was statistically significant. The viability of PC12 cells dropped to the lowest when the CORT concentration was 200μM, and the cells will be treated with a concentration of 200μM in the future. CORT can significantly inhibit the proliferation of PC12 cells, and this inhibitory ability is positively correlated with the CORT concentration, which confirms the successful construction of the in vitro depression model by CORT.

[0043] Furthermore, the effect of LncRNA DANCR on depression was clarified by inhibiting the expression of LncRNA DANCR, and the optimal treatment time of CORT was determined. The specific steps are as follows:

[0044] (1) PC12 cells were cultured overnight in a 6-well plate at 5% CO2 and 37°C in RPMI-1640 containing 10% fetal bovine serum.

[0045] (2) After discarding the cell culture medium, 1 mL of Opti-MEM medium was added, and then siDANCR (the sense sequence is shown in SEQ ID NO: 1, which is 5'-GGTGAAGTAGTCGCACATTTATT-3', and the antisense sequence is shown in SEQ ID NO: 2, which is 5'-TAAATGTGCGACTACTTCACCTT-3', the same below) was added to the cells and cultured in a 5% CO2, 37°C cell culture incubator for 6 h.

[0046] (3) Discard the Opti-MEM medium, add 2 mL of RPMI-1640 medium containing 10% fetal bovine serum, and culture in a 5% CO2, 37°C cell culture incubator for 24 h.

[0047] (4) The cells were digested with trypsin, centrifuged and resuspended to a cell concentration of 80,000 cells / mL, and then inoculated into a 96-well plate (100 μL / well).

[0048] (5) CORT (200 μM) was added to the cells for treatment. After 24 h and 48 h of treatment, 10 μL of CCK8 solution was added to each well and incubated for another 2 h. The absorbance was measured at 450 nm using an ELISA reader.

[0049] The results are as follows Figure 3As shown. The results showed that after detecting cell viability 24 hours later, it was found that by comparing with the 200μM CORT group, the cell viability of the Control group increased significantly, and the cell viability of the si-DANCR+200μM CORT group increased significantly. After detecting cell viability 48 hours later, it was found that compared with the Control+200μM CORT group, the cell viability of the Control group increased significantly, but the cell viability of the si-DANCR+200μM CORT group did not increase. Subsequently, the cells will be treated with 200μM, 24h conditions (compared with the control group, *p<0.05, **p<0.01, ***p<0.001; compared with the si-DANCR group, #p<0.05, ##p<0.01, ###p<0.001).

[0050] Furthermore, the effect of LncRNA DANCR on CORT-induced apoptosis of PC12 cells was studied. The specific steps are as follows:

[0051] (1) PC12 cells were divided into 3 groups, denoted as Group 1-Group 3, where Group 1 was the blank control group, transfected with blank vector siNC and not treated with CORT; Group 2 was the negative control group, transfected with blank vector siNC and treated with 200 μM CORT, and the treatment method was the same as above; Group 3 was the experimental group, transfected with siDANCR and treated with 200 μM CORT, and the treatment method was the same as above. After the cells grew to the logarithmic phase, they were trypsinized and counted, and then seeded into 96-well plates.

[0052] (2) The cells were cultured in a 5% CO2, 37°C cell culture incubator. After 24 h, the cells were collected in a 10 mL centrifuge tube. The number of cells in each sample was 1×10 5 -1×10 6 / mL, centrifuge at 1000rpm for 5min, and discard the culture medium.

[0053] (3) Wash once with PBS buffer and centrifuge at 1000 rpm for 5 min.

[0054] (4) Resuspend the cells in 100 μL of labeling buffer and incubate at room temperature in the dark for 15 min.

[0055] (5) Centrifuge at 1000 rpm for 5 min and rinse the precipitated cells once with PBS.

[0056] (6) Add 5 μL Annexin V-APC and 10 μL 7AAD, vortex gently to mix, and incubate at room temperature in the dark for 15 min.

[0057] (7) Add 485 μL of pre-cooled 1× Binding Buffer to each tube, resuspend and mix, and detect using a flow cytometer. The excitation peak is 488 nm, the emission peak is 575 nm, and the cell fluorescence is detected by flow cytometry. NovoExpress analyzes the data (the horizontal axis is Annexin V-APC; the vertical axis is 7AAD).

[0058] The results are as follows Figure 4 As shown, flow cytometry apoptosis technology was used to detect the apoptosis rate of the CORT group and the control group, and the proportion of apoptotic cells, including early apoptotic cells and late apoptotic cells, was counted. The results showed that compared with the CORT-si-NC group, the apoptosis rate of the Control-si-NC group was lower, and the apoptosis rate of the CORT-si-DANCR group was also lower than that of the CORT-si-NC group, and the difference was statistically significant. The above results suggest that DANCR triggers neuronal apoptosis, and inhibiting DANCR expression can significantly reduce neuronal apoptosis.

[0059] Example 2

[0060] The above examples demonstrate that inhibiting the expression of LncRNA-DANCR helps promote CORT-induced PC12 cell proliferation and inhibits apoptosis of the cells. A large number of studies have shown that inflammation, especially neuroinflammation, is one of the key factors leading to depression and aggravating the condition. Therefore, this example further studies the anti-inflammatory effect of LncRNA-DANCR, and the specific steps are as follows:

[0061] (1) Coating process: Dilute the antigen to be used with coating diluent to an appropriate concentration (generally, the required antigen coating amount is 20-200 μg per well), add 100 μL of antigen to each well, incubate at 37°C for 4 hours, and discard the liquid in the well.

[0062] (2) Blocking the enzyme-labeled reaction wells: Block with 5% calf serum at 37°C for 40 min. Fill each well with blocking solution and remove bubbles from each well. After blocking, wash the wells three times with washing solution, each time for 3 min. Washing method: Aspirate the reaction solution in the wells, fill the wells with washing solution, leave for 2 min, shake slightly, aspirate the solution in the wells, pour off the liquid, and pat dry on absorbent paper.

[0063] (3) Add the cell sample to be tested: Collect PC12 cells in a sterile tube and centrifuge for about 20 minutes (2000-3000 rpm) to collect the supernatant. Dilute the cell suspension with PBS (pH 7.2-7.4) to a cell concentration of 1×10 6After repeated freezing and thawing, centrifuge for about 20 minutes (2000-3000rpm), take the supernatant and add it to the enzyme-labeled reaction wells. Add at least two wells for each sample, 100μL per well, and incubate at 37℃ for 40-60min. Wash the wells three times with washing solution, 3min each time.

[0064] (4) Adding enzyme-labeled antibody: Add 100 μL of enzyme-labeled antibody to each well according to the reference working dilution provided by the enzyme conjugate provider, incubate at 37°C for 30-60 min, and wash as before.

[0065] (5) Add substrate solution: TMB-hydrogen peroxide urea solution is preferred, followed by OPD-hydrogen peroxide substrate solution system; Substrate addition amount: 100 μL per well, incubate at 37°C away from light for 3-5 minutes, add 50 μL stop solution to each well for color development, and measure the experimental results within 20 minutes.

[0066] Test results such as Figure 5 As shown. The results showed that compared with the control group, the expression of inflammatory factors such as TNF-α, IL-6, IL-2, IL-1β, IFN-γ, and G-CSF in the CORT group was significantly increased. After the expression of LncRNA-DANCR in the cells was inhibited by siDANCR, the expression of inflammatory factors such as TNF-α, IL-6, IL-2, IL-1β, IFN-γ, and G-CSF was significantly reduced (compared with the control group, *p<0.05, **p<0.01, ***p<0.001, compared with the CORT group, #p<0.05, ##p<0.01, ###p<0.001). It can be seen that by inhibiting the expression of LncRNA-DANCR, the level of inflammatory factors in the body can be significantly inhibited, which can effectively treat neuroinflammation and prevent the further development of depression.

[0067] In order to clarify the mechanism of action of LncRNA DANCR on depression and inflammation, nucleocytoplasmic separation experiments and fluorescence in situ hybridization experiments (FISH experiments) were used to study its intracellular location.

[0068] The steps of the cell nucleus-cytoplasm separation experiment are as follows: use the Paris TM Kit cell nucleus-cytoplasm separation kit (Invitrogen) to separate the cell lysate into two parts: the nucleus and the cytoplasm, extract RNA using the TRAZOL method, take 1ug RNA and reverse transcribe it into cDNA, and detect the expression of related genes by qRT-PCR (U6 RNA is used as the internal reference gene for nuclear RNA qRT-PCR, and GAPDH is used as the internal reference gene for cytoplasmic RNA qRT-PCR).

[0069] The steps of fluorescence in situ hybridization experiment are as follows:

[0070] (1) PC12 cells were digested with 0.25% trypsin solution and prepared into cell slides. The cells were fixed with 4% paraformaldehyde for 20 min. A 0.3% Triton X-100 solution (2 mL / well) was prepared and incubated for 20 min. The cells were incubated with prehybridization solution at 95°C for 5 min, cooled on ice, and prehybridized at 42°C for 2 h.

[0071] (2) Prepare the probe working solution: probe concentration 1 μg / μL, 1 μL probe + 99 μL probe diluent, incubate at 95°C for 5 min, cool on ice, add probe working solution, hybridize overnight at 42°C; preheat 2×SSC at 37°C, wash on a shaker for 2×5 min; preheat 0.5×SSC at 37°C, wash on a shaker for 15 min; preheat 0.2×SSC at 37°C, wash on a shaker for 15 min; add 100 μl DAPI working solution, incubate at room temperature in the dark for 4 min, rinse with PBS 3 times, 3 min each time; shake dry the slices slightly and seal with anti-fluorescence quenching sealing medium; observe the cell luminescence under a fluorescence microscope and take pictures.

[0072] The experimental results are as follows Figure 6-7 As shown. The relative expression of DANCR in the nucleus and cytoplasm of the control group and the CORT group was detected by nuclear-cytoplasmic separation experiment, with U6 as the nuclear reference gene and GAPDH as the cytoplasmic reference gene. The results showed that DANCR was mainly present in the nucleus in both the control group and the CORT group (*p<0.05, **p<0.01, ***p<0.001).

[0073] Similarly, fluorescence in situ hybridization experiments were used to further confirm the localization of DANCR. The results showed that the DANCR fluorescent probe was distributed in both the cell nucleus and the cytoplasm (scale bar = 20 μM). However, semi-quantitative analysis revealed that there was a lot of overlap between the fluorescence of DANCR and the cell nuclear marker DAPI, suggesting that the subcellular localization of DANCR was mainly in the cell nucleus, which was consistent with the results of the nuclear-cytoplasmic separation experiment (*p < 0.05, **p < 0.01, ***p < 0.001).

[0074] LncRNA has the characteristics of numerous types and diverse functions in eukaryotes. Most LncRNAs are distributed in the nucleus and cytoplasm, and a few are distributed in organelles, such as mitochondria and endoplasmic reticulum. These LncRNAs with different subcellular localizations are given different functions, but it is still unclear how cells sort different LncRNAs to specific subcellular compartments to exert their effects. LncRNAs located in the nucleus or chromosomes often regulate gene expression by affecting epigenetic modifications and transcription processes, and can also activate or inhibit the expression of target genes by directly binding to target genes. However, LncRNAs in the cytoplasm are more likely to participate in translational regulation or play ceRNA functions by adsorbing miRNA. Tissue-specific LncRNAs localized in special organelles can participate in the functional and metabolic regulation of organelles. The present invention detects the expression difference of DANCR in the cytoplasm and nucleus by FISH and cytoplasmic nuclear separation, and finds that DANCR is mainly distributed in the nucleus, indicating that post-transcriptional or post-translational regulation is the main mode of epigenetic regulation of LncRNA DANCR.

[0075] Existing studies have shown that stress granule proteins DDX3X and NLRP3 can interact to activate inflammasomes. Stress granule assembly leads to the sequestration of DDX3X, which in turn inhibits NLRP3 inflammasome activation. Stress granules and NLRP3 inflammasomes compete for DDX3X molecules to coordinate the activation of innate responses under stress and subsequent cell fate determination. Macrophages use the availability of DDX3X to process stress signals and choose between pro-survival stress granules and pyroptotic ASCs. To this end, pull-down experiments, RNA-binding protein immunoprecipitation experiments (RIP experiments) and Western blot experiments were performed to clarify the interaction between LncRNA-DANCR and DDX3X and NLRP3. The specific steps of the pull-down experiment and Western blot experiment are as follows:

[0076] (1) RNA pull-down assay was performed using a magnetic RNA-protein pull-down kit (Axl-Bio) according to the manufacturer's instructions. The probe against DANCR was synthesized by Axl-Bio.

[0077] (2) A mixture of cell lysate and biotinylated RNA probe was hybridized at 4°C for 37 hours, and then the bound complex was recovered using streptavidin-coupled magnetic beads.

[0078] (3) The protein was eluted and purified from the magnetic beads and loaded onto a 12% SDS-PAGE gel for electrophoresis separation.

[0079] (3) After electrophoresis, the membranes were transferred to PVDF membranes and blocked with 5% skim milk powder for 2 h. The membranes were then incubated at 4°C overnight in solutions containing DDX3X primary antibody (Proteintech, 1:2000), NLRP3 primary antibody (Bioss, 1:2000), ASC primary antibody (Proteintech, 1:2000), Caspase-1 primary antibody (Bioss, 1:2000), and GAPDH primary antibody (Proteintech, 1:5000).

[0080] (4) The PVDF membrane was washed with TBST and then combined with HRP secondary antibody (1:1000). After incubation at room temperature for 1 h, the membrane was developed using an ECL luminescence kit and quantitatively analyzed using ImageJ software.

[0081] The RNA binding protein immunoprecipitation experimental steps are as follows: RIP assay was performed using a binding protein immunoprecipitation kit (Axl-Bio) according to the manufacturer's instructions. Cells at approximately 90% confluence were lysed using RIP lysis buffer containing RNase inhibitors and protease inhibitors, and then 100 μL of whole cell extract was incubated with RIP buffer containing magnetic beads coupled to specific antibodies. The negative control was normal rat anti-IgG antibody (Abcam) and the positive control was anti-DDX3X antibody (Proteintech).

[0082] The experimental results are as follows Figure 8-9 As shown. The results showed that by using the experimental group LncRNA DANCR probe and the control probe to perform RNA pulldown experiments, the protein bound to DANCR was pulled, and silver staining was performed after elution. There were obvious bands on the RPD histone silver staining map, indicating that DANCR was bound to the protein. The RIP experiment used RT-qPCR to detect the expression of DANCR in the RIP-RNA product. The results showed that the expression of DANCR in the IP group was significantly higher than that in the negative control IgG group, indicating that there was a binding between LncRNA DANCR and DDX3X (*p<0.05, **p<0.01, ***p<0.001). This proves that DDX3X is the key binding protein of LncRNA DANCR.

[0083] Western blot results showed that ( Fig.10), when DANCR was overexpressed in cells (Control+oe-DANCR group), the levels of DDX3X and inflammasome proteins increased. After DANCR was knocked down by siDANCR in the CORT group (CORT+siDANCR group), the levels of DDX3X and inflammasome proteins decreased (*p<0.05, **p<0.01, ***p<0.001), indicating that LncRNA DANCR can protect DDX3X protein, slow down its degradation, promote DDX3X stability, increase DDX3X protein abundance, and then mediate DDX3X protein to promote inflammasome activation. Inhibiting the expression level of LncRNA DANCR can help reduce the expression level of DDX3X protein in the body, thereby inhibiting the occurrence and further progression of inflammatory response.

[0084] The present invention has found through a large number of studies that LncRNA DANCR plays an important role in the occurrence and development of depression. Both in vivo and in vitro experiments have proved that LncRNA DANCR is one of the key factors that cause depression and promote the development of depression. LncRNA DANCR can not only inhibit the proliferation of nerve cells, but also promote the apoptosis of nerve cells. After the expression level of LncRNA DANCR is inhibited by an inhibitor, the proliferation of nerve cells can be effectively promoted and the apoptosis of nerve cells can be inhibited. At the same time, LncRNA DANCR has a key effect on inflammation, especially neuroinflammation and its related inflammatory factors. The experimental results show that by inhibiting the expression of LncRNA-DANCR, the levels of inflammatory factors such as TNF-α, IL-6, IL-2, IL-1β, IFN-γ, G-CSF, etc. in the body can be significantly inhibited, thereby effectively treating neuroinflammation and preventing the further development of depression. Through in-depth research on its mechanism of action, it was found that LncRNA DANCR is mainly located in the cell nucleus, and there is an obvious interaction between LncRNA DANCR and DDX3X. LncRNA DANCR can protect DDX3X protein, slow down its degradation, promote DDX3X stability, increase DDX3X protein abundance, and then mediate DDX3X protein to promote inflammasome activation. Inhibiting the expression level of LncRNA DANCR can help reduce the expression level of DDX3X protein in the body, thereby inhibiting the occurrence and further progression of inflammatory response.

[0085] The above specific implementation method part specifically introduces the analytical method involved in the present invention. It should be noted that the above introduction is only to help those skilled in the art better understand the method and ideas of the present invention, rather than limiting the relevant content. Without departing from the principle of the present invention, those skilled in the art may also make appropriate adjustments or modifications to the present invention, and the above adjustments and modifications shall also fall within the scope of protection of the present invention.

Claims

1. Use of lncRNA DANCR inhibitors in the preparation of drugs for preventing and / or treating depression.

2. The use according to claim 1, characterized in that: The LncRNA DANCR inhibitor is selected from siRNA designed based on the LncRNA DANCR gene.

3. The use according to claim 1, characterized in that: The siRNA sequence designed based on the LncRNA DANCR gene is shown in SEQ ID NO:

1.

4. Use of lncRNA DANCR inhibitors in the preparation of drugs for treating neuroinflammation and / or improving physiological indicators related to neuroinflammation.

5. The use according to claim 4, characterized in that: The LncRNA DANCR inhibitor is selected from siRNA designed based on the LncRNA DANCR gene.

6. The use according to claim 4, characterized in that: The siRNA sequence designed based on the LncRNA DANCR gene is shown in SEQ ID NO:

1.

7. The use according to claim 4, characterized in that: The physiological indicators related to neuroinflammation are selected from one or more of TNF-α, IL-6, IL-2, IL-1β, IFN-γ, G-CSF, and DDX3X.

8. A pharmaceutical composition for preventing and / or treating depression, characterized in that: It includes a LncRNA DANCR inhibitor and pharmaceutically acceptable excipients.

9. The pharmaceutical composition according to claim 8, characterized in that The LncRNA DANCR inhibitor is selected from siRNA designed based on the LncRNA DANCR gene.

10. The pharmaceutical composition according to claim 8, characterized in that The siRNA sequence designed based on the LncRNA DANCR gene is shown in SEQ ID NO: 1.

Citation Information

Patent Citations

  • Identification and targeted modulation of gene signaling networks

    WO2018204764A1

  • Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

    WO2024076989A1